MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany
HAMBURG, Germany, May 21, 2025 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is proud to unveil its latest innovation, PrepALL, a flexible liquid handling system, along with the latest version of the Smart8 at SLAS Europe 2025, taking place from May 20–22 in Hamburg. Featuring advanced robotics, AI integration, and modular platforms, MGI's automation portfolio addresses critical challenges in genomics, drug discovery, synthetic biology, and molecular diagnostics—empowering labs of all sizes to scale research efficiently.
PrepALL: Compact, Affordable Automation for Flexible Pipetting
The PrepALL Flexible Liquid Handling Platform simplifies complex laboratory tasks while maintaining enterprise-level performance—without the high costs typically associated with traditional systems. Compact yet powerful, PrepALL is ideal for laboratories adopting automation for the first time or scaling existing research capacity.
Key Features Include:
Space-saving design: Occupies just 0.7 m², with 16 SBS deck positions (expandable to 41).
High-precision pipetting: 8 independent channels support 0.5–1200 µL volumes with CVs (coefficients of variation) of less than 3% (1–50 µL) and <1% (50–1200 µL). It supports pLLD/cLLD, liquid level tracking, and anti-dripping, so that it reduces dead volume and improves pipetting accuracy.
Plug-and-play setup and easy to use: Integrated with a visual system, it can achieve automatic consumables identification and automatic position calibration
Full traceability: Built-in sensors and data logging ensure reproducibility and consistency.
Leveraging advanced vision-based AI, PrepALL delivers high-precision performance in critical applications such as nucleic acid extraction, plasmid construction, sample preparation, and NGS library prep. Designed for global accessibility, it addresses cost and complexity barriers with a scalable, modular design and open APIs. Ideal for both entry-level and high-throughput environments, PrepALL empowers smaller labs to scale without costly infrastructure overhauls.
'PrepALL represents a major leap in lab automation, giving labs of all sizes the ability to streamline complex workflows with unmatched affordability and reliability. It's a bold step in our mission to democratize cutting-edge tools and accelerate scientific discovery worldwide.' said Dr. Christian Zimmerman, VP of Sales at MGI Europe and Africa.
Scalable Automation Ecosystem for Every Lab
MGI's automation portfolio is among the most versatile in the industry, designed to meet diverse laboratory needs while ensuring scalability and ease of use. At SLAS Europe 2025, MGI also presents Smart 8, a globally recognized solution launched in 2022. Smart 8 features eight-channel pipetting, and smart gripper technology. The new enhancement introduces AI-optimized pipetting for up to 20% faster cycle times, including nucleic acid extraction, microbial screening, and library preparation. This update ensures higher reproducibility and efficiency, making the Smart 8 an ideal partner for labs seeking reliable automation while remaining cost-effective.
The enhanced capabilities of the Smart 8 will cater to academic institutions, biotech startups, and clinical labs, offering a competitive edge in high-throughput research. By reducing manual intervention, the system accelerates time-to-results, enabling researchers to focus on data analysis and discovery.
Affordable, Scalable, Smart: The MGI Automation Edge
MGI stands out in the lab automation market by prioritizing cost-effectiveness, scalability, and global accessibility. Designed to democratize advanced technology, MGI empowers researchers across diverse fields—from precision medicine to agriculture—regardless of budget constraints.
MGI provides a comprehensive portfolio that covers the entire workflow, from sample extraction and preparation to sequencing and data analysis. This all-in-one solution enhance chances to meet customers' diversified demand under one system and brand and ensures compatibility among various systems, simplifying the overall experimental workflow.
These advantages have positioned MGI as a trusted partner in more than 100 countries, accelerating breakthroughs in genomics, synthetic biology, and beyond. During global health crises, systems like the Platforms like the MGISP-960 and MGISTP-7000 have processed millions of samples, demonstrating MGI's ability to deliver robust solutions under pressure.
MGI invites researchers, lab managers, and industry professionals to explore its latest automation solutions at SLAS Europe 2025. Visit MGI's booth#516 to see the enhanced innovations in action.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
20 minutes ago
- Malaysian Reserve
MGI Tech Partners with Asia Pathogen Genomics Initiative to Advance Pathogen Genomics for Public Health in Asia
SINGAPORE, June 11, 2025 /PRNewswire/ — MGI Tech Co., Ltd. ('MGI'), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and Asia Pathogen Genomics Initiative ('Asia PGI'), part of the Duke-NUS Centre for Outbreak Preparedness (COP), have recently announced collaboration aimed at enhancing pathogen genomics sequencing efforts across Asia. This collaboration underscores a shared commitment to supporting public health initiatives through advanced life science technology. As part of this collaboration, MGI and Asia PGI will jointly democratize the pathogen genomics sequencing technology in Singapore and across Asia. The collaborative efforts will include hosting webinars to provide practical knowledge in pathogen genomics sequencing and delivering hands-on technical training to institutions and laboratories aimed at improving capacity development in pathogen detection. In addition, MGI also announced the launch of the MGI APAC Pandemic Preparedness Program (PPP) to strengthen the capabilities of genomics institutions and laboratories in pathogen surveillance. In collaboration with Asia PGI, the PPP aims to broaden the scope of pathogen surveillance solutions available to partner countries. The program offers a differentiated and sustainable alternative, focusing on application-centric and workflow-driven solutions. For example, it supports the development of equitable, effective, relevant, and validated workflow solutions to address acute infectious diseases. 'At the Duke-NUS Centre for Outbreak Preparedness, we believe that equitable access to pathogen genomic sequencing is fundamental to strengthening health security across South and Southeast Asia,' said Paul Pronyk, Director of COP. 'By collaborating with industry partners such as MGI, we are committed to ensuring that all communities in our region benefit from the latest advances in pathogen genomics – enabling early detection, informed response and ultimately, a healthier future for all.' 'We are proud to partner with Asia PGI to accelerate the application of cutting-edge sequencing technology in pathogen genomics,' said Roy Tan, General Manager of MGI Asia Pacific. 'Pathogen control is a pressing challenge for many countries in Asia. This partnership aims to improve the accessibility of pathogen genomics, empowering researchers and public health professionals in their fight against infectious diseases.' In response to the growing demand for rapid and precise detection of infectious diseases, MGI has developed a diverse array of comprehensive products for various applications, including metagenomic sequencing, targeted sequencing, and whole genome sequencing of pathogenic microorganisms. Looking ahead, MGI is committed to continuing its innovation, providing automated, convenient, and efficient core tools for pathogen identification, drug resistance analysis, and traceability. For more information of PPP, please visit: About the Duke-NUS Centre for Outbreak Preparedness (COP) and its Asia Pathogen Genomic Initiative (Asia PGI) The Duke-NUS Centre for Outbreak Preparedness (COP) was established in 2022 to address the growing need for enhanced preparedness and response to infectious disease outbreaks in the Asian region. With a mission to bridge the gap between research, training, policy and practice, COP aims to enhance regional health security across South and Southeast Asia. The Asia Pathogen Genomic Initiative (Asia PGI) is a flagship initiative of COP, aiming to harness scientific and technical partnerships across Singapore and Asia to advance genomic sequencing for infectious disease elimination. For more information, please visit About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and 10 centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. For more information, please visit the MGI website or connect with us on Twitter, LinkedIn or YouTube.
The Star
3 hours ago
- The Star
Chinese firm to undertake Lao agriculture and forestry development project
Bouachanh Sihavong (right) and Wang Li signing agreement on transport and road development. - VT VIENTIANE: The State Enterprise for Agricultural Service of the Ministry of Agriculture and Forestry has signed a Memorandum of Understanding (MoU) with the Shandong Hi-Speed Road & Bridge International Engineering Co, Ltd of China. The agreement authorises the company to carry out a feasibility study of agricultural and forestry development and the processing of agricultural and forestry products along Road 1F, as well as the upgrade of the road to better facilitate the transport of agricultural goods for export. The MoU was signed in Vientiane on June 6 by the Director of the State Enterprise for Agriculture Service, Bouachanh Sihavong, and the Chairman of Shandong Hi-Speed Road & Bridge International Engineering Co, Ltd, Wang Li. Speaking at the ceremony, Bouachanh Sihavong said 'This cooperation will contribute to the transformation from traditional production models to a modern industry linked to value-added processing with the provision of production factors and services as a focus to resolve problems that have occurred in the past.' 'This includes damage caused by climate change (floods, droughts, pest infestations), high production costs, no market for products produced, the production process does not follow clean agricultural principles, the market does not accept the product, transport costs are expensive, etc.' It will also enable people living in the project area to boost their incomes by improving their farming skills so they can grow more crops on a commercial basis in a group format, supported by strong cooperatives, a good information learning system, early warning of disasters, and access to a wide range of services such as land planning, water supply, crop varieties, farming methods, maintenance, marketing information, and credit schemes, Bouachanh said. 'We have included a study of the development of freight transport in the agricultural development study project from the beginning.' 'This partnership will help to reduce the government's investment budget by attracting grants and qualified entrepreneurs to invest in infrastructure for production and processing,' he added. If the project goes according to plan, it will move forward to a higher level and the consideration of a joint venture. The results of the collaboration are expected to increase annual crop yields. It is envisaged that the rice harvest will increase by more than 500,000 tonnes, vegetable crops by more than 1,000,000 tonnes, fruit by at least 600,000 tonnes, and livestock by at least 300,000 tonnes. It is also hoped that fish farming will involve at least 500,000 more people a year, and that agricultural and forestry tourism will increase by at least 500,000 people a year, which will contribute an additional 25-30 per cent to Gross Domestic Product (GDP) from agriculture each year. 'I believe that if each of the project goals set for this study and development is achieved, it will not only contribute to the production and processing of agricultural products and generate additional income, it will also become a model of modern commercial agriculture linked to sustainable tourism with public participation,' Bouachanh said. This will involve the sharing of information, create more jobs for young people, and can be expanded to more parts of the country, he added. - Vientiane Times/ANN
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023； First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, 'This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible.' [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@
